Published in Medical Letter on the CDC and FDA, May 2nd, 2004
The FDA's pre-IND meeting programs are designed to provide sponsors with advance, guidance, and input on drug development programs.
Richard Rosenbloom, MD, chief operating officer of Quigley Pharma Inc., stated, "Quigley Pharma received guidance from the FDA's Division of Anesthetic, Critical Care and Addiction Drug Products, on the next steps...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA